Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Long-Term Investments (2016)

Historic Long-Term Investments for Perspective Therapeutics (CATX) over the last 3 years, with Q2 2016 value amounting to $3.0 million.

  • Perspective Therapeutics' Long-Term Investments fell 4178.32% to $3.0 million in Q2 2016 from the same period last year, while for Jun 2016 it was $3.0 million, marking a year-over-year decrease of 4178.32%. This contributed to the annual value of $3.0 million for FY2016, which is 4178.32% down from last year.
  • Perspective Therapeutics' Long-Term Investments amounted to $3.0 million in Q2 2016, which was down 4178.32% from $5.2 million recorded in Q1 2016.
  • In the past 5 years, Perspective Therapeutics' Long-Term Investments registered a high of $5.4 million during Q2 2014, and its lowest value of $3.0 million during Q2 2016.
  • Its 3-year average for Long-Term Investments is $4.8 million, with a median of $5.2 million in 2015.
  • As far as peak fluctuations go, Perspective Therapeutics' Long-Term Investments crashed by 545.46% in 2015, and later tumbled by 4178.32% in 2016.
  • Quarter analysis of 3 years shows Perspective Therapeutics' Long-Term Investments stood at $5.4 million in 2014, then decreased by 4.4% to $5.2 million in 2015, then tumbled by 42.42% to $3.0 million in 2016.
  • Its Long-Term Investments was $3.0 million in Q2 2016, compared to $5.2 million in Q1 2016 and $5.2 million in Q4 2015.